Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Sees Large Decrease in Short Interest

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) saw a significant drop in short interest during the month of March. As of March 15th, there was short interest totalling 64,700 shares, a drop of 28.0% from the February 28th total of 89,800 shares. Approximately 0.1% of the shares of the company are short sold. Based on an average daily trading volume, of 87,000 shares, the days-to-cover ratio is presently 0.7 days.

Xtant Medical Stock Performance

Shares of NYSEAMERICAN:XTNT traded up $0.00 on Tuesday, hitting $0.47. The company’s stock had a trading volume of 6,160 shares, compared to its average volume of 99,306. The firm has a market capitalization of $65.35 million, a P/E ratio of -3.62 and a beta of 0.35. The company has a quick ratio of 0.88, a current ratio of 2.12 and a debt-to-equity ratio of 0.42. Xtant Medical has a 12 month low of $0.33 and a 12 month high of $1.14. The company’s 50-day moving average price is $0.53.

Institutional Investors Weigh In On Xtant Medical

A hedge fund recently raised its stake in Xtant Medical stock. Geode Capital Management LLC lifted its stake in shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) by 70.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 515,006 shares of the medical device company’s stock after acquiring an additional 212,394 shares during the quarter. Geode Capital Management LLC owned 0.37% of Xtant Medical worth $348,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 69.33% of the company’s stock.

About Xtant Medical

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.